AGIOS PHARMACEUTICALS INC

AGIO stock represents ownership in Agios Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for rare diseases and cancer. The ticker trades on the Nasdaq Global Select Market under the symbol AGIO. The company's pipeline includes treatments for conditions such as pyruvate kinase deficiency and acute myeloid leukemia, and its shares offer investors exposure to the biotechnology sector.

For the most recent AGIO stock price movement and performance data, please refer to the live chart and performance figures displayed on this page. Stock performance can fluctuate based on clinical trial updates, regulatory news, and broader market conditions. The page provides up-to-date information on daily, weekly, and year-to-date changes.

Evaluating AGIO's valuation involves analyzing its price-to-sales ratio, price-to-book ratio, and cash position, especially since the company may not be consistently profitable. Investors often compare these metrics to peers in the biotechnology industry and consider pipeline progress, partnership deals, and potential market opportunities for its therapies. The page's valuation section provides relevant metrics.

To buy AGIO stock, open a brokerage account with a registered U.S. broker. Once funded, search for the ticker AGIO and place a buy order during regular market hours (9:30 a.m. to 4:00 p.m. ET). Alternatively, some brokers allow fractional shares. Ensure you review order types such as market or limit orders before executing a trade.

Agios Pharmaceuticals does not currently pay dividends on its common stock. As a clinical-stage biopharmaceutical company, it reinvests earnings into research and development. For the latest dividend information, check the dividend section on this page, which reflects any updates from the company.

Key risks for AGIO include clinical trial failures, regulatory delays, competition from other therapies, and reliance on key partnerships. As a biotech with a focused pipeline, negative results or adverse events can significantly impact the share price. Additionally, the company may need to raise capital, potentially diluting shareholders. Investors should review SEC filings for detailed risk factors.